Hoersholm; March 18th, 2016 – Medical Prognosis Institute A/S (MPI.CO) announced the Company’s financial results for the year ended December 31, 2015.
Annual Report 2015
The Board of Directors for Medical Prognosis Institute A/S has today discussed the audited Annual Report for 2015. The Annual Report was approved and will be recommended for approval at the Annual General Meeting.
Annual General Meeting
The Annual General Meeting will be held on the 20 April 2016. A call for and Agenda will be sent in accordance with the Articles of Association.
Interim Report, Half Year per 30. June 2016
The Company announces half-year report for the period of 1. January – 30. June 2016 on 31 August 2016.
Financial performance
-
Revenue amounted to DKK 5,837,783 in 2015 (last year DKK 4,315,459)
-
Profit/loss before financial income and expenses amounted to DKK -11,036,202 (last year DKK -7,074,742)
-
This loss was in line with the guidance given together with the half-year interim report
-
Cash at bank and in hand at year end DKK 5,278,013 (last year DKK 16,020,922)
The Annual Report will be available at www.medical-prognosis.com.
About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM)
MPI’s lead product, the DRP(TM) Diagnostic Platform, is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. MicroRNA is used on certain products whereas the messengerRNA is more broadly useable and more validated. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.
About MPI
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI’s exceptional opportunity to personalize cancer treatment – begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.
For further information, please contact
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.D.
E-mail: [email protected]
Phone: +45 21 60 89 22
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark
